MX2016013684A - Composicion farmaceutica que contiene derivado de hidantoina. - Google Patents

Composicion farmaceutica que contiene derivado de hidantoina.

Info

Publication number
MX2016013684A
MX2016013684A MX2016013684A MX2016013684A MX2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
containing pharmaceutical
hydantoin derivative
formula
hydantoin
Prior art date
Application number
MX2016013684A
Other languages
English (en)
Other versions
MX371090B (es
Inventor
Kitamura Hidetomo
Tamura Tatsuya
Noda Horoshi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2016013684A publication Critical patent/MX2016013684A/es
Publication of MX371090B publication Critical patent/MX371090B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica para inducir una acción de absorción del hueso y/o cartílago, que incluye como un componente eficaz de la misma un compuesto indicado por la fórmula general (1) o una sal farmacológicamente aceptable del mismo (en la fórmula, R1, R2, R3, y R4 son como se definen en las Reivindicaciones).
MX2016013684A 2014-06-09 2014-06-09 Composicion farmaceutica que contiene derivado de hidantoina. MX371090B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/065262 WO2015189901A1 (ja) 2014-06-09 2014-06-09 ヒダントイン誘導体含有医薬組成物

Publications (2)

Publication Number Publication Date
MX2016013684A true MX2016013684A (es) 2017-01-20
MX371090B MX371090B (es) 2020-01-16

Family

ID=54833033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013684A MX371090B (es) 2014-06-09 2014-06-09 Composicion farmaceutica que contiene derivado de hidantoina.

Country Status (10)

Country Link
US (1) US9993462B2 (es)
EP (1) EP3153166B1 (es)
KR (2) KR102266021B1 (es)
CN (2) CN106572994B (es)
AU (1) AU2014397042B2 (es)
BR (1) BR112016003511B8 (es)
CA (1) CA2949023C (es)
MX (1) MX371090B (es)
RU (1) RU2701168C2 (es)
WO (2) WO2015189901A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2930176T3 (en) * 2012-12-10 2018-03-19 Chugai Pharmaceutical Co Ltd hydantoin derivatives
TW202019416A (zh) 2018-07-30 2020-06-01 日商中外製藥股份有限公司 乙內醯脲衍生物的固體分散體
JPWO2024143501A1 (es) 2022-12-28 2024-07-04

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
JP3913983B2 (ja) 1998-12-11 2007-05-09 エフ．ホフマン−ラ ロシュ アーゲー ＴＮＦ−α阻害剤としての環式ヒドラジン誘導体
CA2420759A1 (en) 2000-08-30 2003-02-27 Daishiro Miura Parathyroid hormone production inhibitors containing vitamin d3 derivatives
CA2425283A1 (en) 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070123548A1 (en) 2004-02-11 2007-05-31 Cowan David J Pth agonists
WO2006041830A2 (en) 2004-10-07 2006-04-20 Merck & Co., Inc. Cgrp receptor antagonists
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
CA2689560A1 (en) * 2007-06-07 2008-12-11 F.Hoffmann-La Roche Ag Prolinamide derivatives as nk3 antagonists
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
EP2433940B9 (en) 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
DK2930176T3 (en) * 2012-12-10 2018-03-19 Chugai Pharmaceutical Co Ltd hydantoin derivatives

Also Published As

Publication number Publication date
KR20170010354A (ko) 2017-01-31
US20170112812A1 (en) 2017-04-27
KR102266021B1 (ko) 2021-06-16
US9993462B2 (en) 2018-06-12
EP3153166A1 (en) 2017-04-12
KR102382331B1 (ko) 2022-04-01
EP3153166A4 (en) 2018-01-17
BR112016003511B1 (pt) 2022-11-08
BR112016003511B8 (pt) 2023-10-03
AU2014397042A1 (en) 2016-02-11
RU2016113896A3 (es) 2018-07-18
RU2701168C2 (ru) 2019-09-25
BR112016003511A8 (pt) 2018-01-30
CA2949023A1 (en) 2015-12-17
CN106535892B (zh) 2020-09-18
CA2949023C (en) 2021-10-12
RU2016113896A (ru) 2018-07-18
CN106572994A (zh) 2017-04-19
MX371090B (es) 2020-01-16
BR112016003511A2 (es) 2017-08-01
CN106572994B (zh) 2020-09-18
AU2014397042B2 (en) 2020-04-09
EP3153166B1 (en) 2022-08-03
CN106535892A (zh) 2017-03-22
KR20170010439A (ko) 2017-01-31
WO2015189901A1 (ja) 2015-12-17
WO2015190451A1 (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
PH12016501813A1 (en) 1,3-benzodioxole derivative
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
GEAP201814248A (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MX383577B (es) Derivados sustituidos de guanidina.
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
GEP20186893B (en) Pyrazines modulators of gpr6
PH12016500461A1 (en) Polyethylene glycol-containing composition
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
PH12015501146A1 (en) Hydantoin derivative
MX371090B (es) Composicion farmaceutica que contiene derivado de hidantoina.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX387920B (es) Peptidos antagonistas de prgc.
EA201690908A1 (ru) Пиразолопиримидиновые соединения
PH12017501134A1 (en) Fumagillol derivatives
MX2019007786A (es) Compuestos sustituidos de guanidina.
TN2014000308A1 (en) Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration